144 related articles for article (PubMed ID: 18808317)
1. Expert opinion on tilarginine in the treatment of shock.
Howes LG; Brillante DG
Expert Opin Investig Drugs; 2008 Oct; 17(10):1573-80. PubMed ID: 18808317
[TBL] [Abstract][Full Text] [Related]
2. Effect of tilarginine acetate in patients with acute myocardial infarction and cardiogenic shock: the TRIUMPH randomized controlled trial.
; Alexander JH; Reynolds HR; Stebbins AL; Dzavik V; Harrington RA; Van de Werf F; Hochman JS
JAMA; 2007 Apr; 297(15):1657-66. PubMed ID: 17387132
[TBL] [Abstract][Full Text] [Related]
3. Effects of a nitric oxide synthase inhibitor in humans with septic shock.
Petros A; Lamb G; Leone A; Moncada S; Bennett D; Vallance P
Cardiovasc Res; 1994 Jan; 28(1):34-9. PubMed ID: 7509259
[TBL] [Abstract][Full Text] [Related]
4. Response of the septic vasculature to prolonged vasopressor therapy with N(omega)-monomethyl-L-arginine and epinephrine in canines.
Freeman BD; Zeni F; Banks SM; Eichacker PQ; Bacher JD; Garvey EP; Tuttle JV; Jurgensen CH; Natanson C; Danner RL
Crit Care Med; 1998 May; 26(5):877-86. PubMed ID: 9590318
[TBL] [Abstract][Full Text] [Related]
5. Effect of nitric oxide synthase inhibition on haemodynamics and outcome of patients with persistent cardiogenic shock complicating acute myocardial infarction: a phase II dose-ranging study.
Dzavík V; Cotter G; Reynolds HR; Alexander JH; Ramanathan K; Stebbins AL; Hathaway D; Farkouh ME; Ohman EM; Baran DA; Prondzinsky R; Panza JA; Cantor WJ; Vered Z; Buller CE; Kleiman NS; Webb JG; Holmes DR; Parrillo JE; Hazen SL; Gross SS; Harrington RA; Hochman JS;
Eur Heart J; 2007 May; 28(9):1109-16. PubMed ID: 17459901
[TBL] [Abstract][Full Text] [Related]
6. Tissue oxygenation and hemodynamic response to NO synthase inhibition in septic shock.
Broccard A; Hurni JM; Eckert P; Liaudet L; Schaller MD; Lazor R; Perret C; Feihl F
Shock; 2000 Jul; 14(1):35-40. PubMed ID: 10909891
[TBL] [Abstract][Full Text] [Related]
7. The tragedy of TRIUMPH for nitric oxide synthesis inhibition in cardiogenic shock: where do we go from here?
Bailey A; Pope TW; Moore SA; Campbell CL
Am J Cardiovasc Drugs; 2007; 7(5):337-45. PubMed ID: 17953472
[TBL] [Abstract][Full Text] [Related]
8. Beneficial effects of L-canavanine, a selective inhibitor of inducible nitric oxide synthase, on lactate metabolism and muscle high energy phosphates during endotoxic shock in rats.
Levy B; Valtier M; de Chillou C; Bollaert PE; Cane D; Mallie JP
Shock; 1999 Feb; 11(2):98-103. PubMed ID: 10030795
[TBL] [Abstract][Full Text] [Related]
9. L-NMMA (a nitric oxide synthase inhibitor) is effective in the treatment of cardiogenic shock.
Cotter G; Kaluski E; Blatt A; Milovanov O; Moshkovitz Y; Zaidenstein R; Salah A; Alon D; Michovitz Y; Metzger M; Vered Z; Golik A
Circulation; 2000 Mar; 101(12):1358-61. PubMed ID: 10736276
[TBL] [Abstract][Full Text] [Related]
10. The dual effects of nitric oxide synthase inhibitors on ischemia-reperfusion injury in rat hearts.
Kobara M; Tatsumi T; Takeda M; Mano A; Yamanaka S; Shiraishi J; Keira N; Matoba S; Asayama J; Nakagawa M
Basic Res Cardiol; 2003 Sep; 98(5):319-28. PubMed ID: 12955405
[TBL] [Abstract][Full Text] [Related]
11. Increase in gastric intramucosal hydrogen ion concentration following endotoxin challenge in the rat and the actions of nitric oxide synthase inhibitors.
Lamarque D; Whittle BJ
Clin Exp Pharmacol Physiol; 2001 Mar; 28(3):164-8. PubMed ID: 11207670
[TBL] [Abstract][Full Text] [Related]
12. Postsynaptic α1-Adrenergic Vasoconstriction Is Impaired in Young Patients With Vasovagal Syncope and Is Corrected by Nitric Oxide Synthase Inhibition.
Stewart JM; Suggs M; Merchant S; Sutton R; Terilli C; Visintainer P; Medow MS
Circ Arrhythm Electrophysiol; 2016 Aug; 9(8):. PubMed ID: 27444639
[TBL] [Abstract][Full Text] [Related]
13. Nitric oxide in the pathogenesis of sepsis.
Symeonides S; Balk RA
Infect Dis Clin North Am; 1999 Jun; 13(2):449-63, x. PubMed ID: 10340177
[TBL] [Abstract][Full Text] [Related]
14. In vivo quantification of endotoxin-induced nitric oxide production in pigs from Na15NO3-infusion.
Santak B; Radermacher P; Iber T; Adler J; Wachter U; Vassilev D; Georgieff M; Vogt J
Br J Pharmacol; 1997 Dec; 122(8):1605-10. PubMed ID: 9422804
[TBL] [Abstract][Full Text] [Related]
15. Tilarginine in patients with acute myocardial infarction and cardiogenic shock.
Teerlink T
JAMA; 2007 Sep; 298(9):971-2; author reply 972-3. PubMed ID: 17785640
[No Abstract] [Full Text] [Related]
16. Combined treatment with a nonselective nitric oxide synthase inhibitor (l-NMMA) and indomethacin increases ductus constriction in extremely premature newborns.
Keller RL; Tacy TA; Fields S; Ofenstein JP; Aranda JV; Clyman RI
Pediatr Res; 2005 Dec; 58(6):1216-21. PubMed ID: 16306196
[TBL] [Abstract][Full Text] [Related]
17. The multiple organ dysfunction syndrome caused by endotoxin in the rat: attenuation of liver dysfunction by inhibitors of nitric oxide synthase.
Thiemermann C; Ruetten H; Wu CC; Vane JR
Br J Pharmacol; 1995 Dec; 116(7):2845-51. PubMed ID: 8680715
[TBL] [Abstract][Full Text] [Related]
18. Nitric oxide and the haemodynamic profile of endotoxin shock in the conscious mouse.
Rees DD; Monkhouse JE; Cambridge D; Moncada S
Br J Pharmacol; 1998 Jun; 124(3):540-6. PubMed ID: 9647479
[TBL] [Abstract][Full Text] [Related]
19. Effects of N-methyl-L-arginine on cardiac and regional blood flow in a dog endotoxin shock model.
Doursout MF; Kilbourn RG; Hartley CJ; Chelly JE
J Crit Care; 2000 Mar; 15(1):22-9. PubMed ID: 10757195
[TBL] [Abstract][Full Text] [Related]
20. Tilarginine in patients with acute myocardial infarction and cardiogenic shock.
Kielstein JT; Sydow K; Thum T
JAMA; 2007 Sep; 298(9):971; author reply 972-3. PubMed ID: 17785641
[No Abstract] [Full Text] [Related]
[Next] [New Search]
